Å.Â. ßÍÈ, Ë.À. ÊÀÒÀÐÃÈÍÀ, Í.Á. ×ÅÑÍÎÊÎÂÀ, Î.Â. ÁÅÇÍÎÑ, À.Þ. ÑÀÂ×ÅÍÊÎ, Â.À. ÂÛÃÎÄÈÍ, Å.Þ. ÃÓÄÊÎÂÀ, À.À. ÇÀÌßÒÍÈÍ (ÌË.), Ì.Â. ÑÊÓËÀ×Å ÍÈÈ ãëàçíûõ áîëåçíåé èì. Ãåëüìãîëüöà, ã. Ìîñêâà Ïåðâûé Ìîñêîâñêèé ãîñóäàðñòâåííûé ìåäèöèíñêèé óíèâåðñèòåò èì. È.Ì. Ñå÷åíîâà Ìîñêîâñêèé ãîñóäàðñòâåííûé óíèâåðñèòåò èì. Ì.Â. Ëîìîíîñîâà

Results on open randomized controlled comparative clinical trial on effi cacy and safety of novel pharmaceautical Visomitin in the treatment of ‘dry eye’ patients are reported. Visomitin is the fi rst pharmaceautical containing mitochondria-targeted antioxidant as an active substance. In this study Visomitin showed high effi cacy in dry eye treatment. Results on recovery of subjective condition, visual acuity, clinical parameters and diagnostic tests data are reported.